Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in BBOT held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Cormorant Asset Management, LP | 17.9M | $136.2M | 0.0% | 22.318% | 6.98% |
| 2 | DEERFIELD MANAGEMENT COMPANY, L.P. | 4.9M | $37.2M | 0.0% | 6.099% | 0.39% |
| 3 | Omega Fund Management, LLC | 3.3M | $25.1M | 0.0% | 4.107% | 13.50% |
| 4 | EcoR1 Capital, LLC | 2.8M | $21.5M | 0.0% | 3.524% | 1.05% |
| 5 | Alphabet Inc. | 2.8M | $21.5M | 0.0% | 3.524% | 0.02% |
| 6 | WELLINGTON MANAGEMENT GROUP LLP | 2.8M | $21.3M | -1.0% | 3.482% | 0.00% |
| 7 | Enavate Sciences GP, LLC | 2.6M | $20.0M | 0.0% | 3.279% | 5.80% |
| 8 | CITADEL ADVISORS LLC | 2.6M | $19.9M | +3.5% | 3.268% | 0.00% |
| 9 | Novo Holdings A/S | 2.3M | $17.1M | +2.9% | 2.809% | 1.00% |
| 10 | BlackRock, Inc. | 2.2M | $16.4M | +3.1% | 2.689% | 0.00% |
| 11 | VANGUARD CAPITAL MANAGEMENT LLC | 2.0M | $15.3M | +272.5% | 2.504% | 0.00% |
| 12 | Laurion Capital Management LP | 2.0M | $15.3M | +4.2% | 2.500% | 0.39% |
| 13 | ARMISTICE CAPITAL, LLC | 1.8M | $13.4M | +32.8% | 2.202% | 0.16% |
| 14 | STATE STREET CORP | 1.0M | $7.9M | +358.1% | 1.294% | 0.00% |
| 15 | Aisling Capital Management LP | 1.0M | $7.8M | 0.0% | 1.271% | 1.64% |
| 16 | Opaleye Management Inc. | 700K | $5.3M | +1213.8% | 0.874% | 0.48% |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 622K | $4.7M | +7.4% | 0.777% | 0.00% |
| 18 | Granahan Investment Management, LLC | 559K | $4.3M | +141.7% | 0.697% | 0.15% |
| 19 | SPHERA FUNDS MANAGEMENT LTD. | 461K | $3.5M | — | 0.576% | 0.46% |
| 20 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 400K | $3.0M | 0.0% | 0.499% | 0.00% |
| 21 | ROYCE & ASSOCIATES LP | 385K | $2.9M | -39.5% | 0.481% | 0.02% |
| 22 | Catalio Capital Management, LP | 318K | $2.4M | — | 0.398% | 0.46% |
| 23 | VANGUARD FIDUCIARY TRUST CO | 292K | $2.2M | +14.6% | 0.364% | 0.00% |
| 24 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 287K | $2.2M | -1.5% | 0.358% | 0.00% |
| 25 | Casdin Capital, LLC | 282K | $2.2M | 0.0% | 0.352% | 0.11% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in BBOT — a direct measure of their conviction.
Filings activity in BBOT during Q2 2026, grouped by how each filer changed its position.
4 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 63 | 3.1% | 73.58% | +2.09 pp | $447M | 12% |
| Q1 2026 | 65 | +23% | 71.49% | 1.30 pp | $508M | 32% |
| Q4 2025 | 53 | +29% | 72.79% | +1.87 pp | $746M | +15% |
| Q3 2025 | 41 | — | 70.92% | — | $647M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying BBOT stock.
Based on Q2 2026 13F filings, institutional ownership of BridgeBio Oncology Therapeutics Inc. stands at 73.6%, held across 63 reporting institutions.
Cormorant Asset Management, LP is the largest reported institutional holder of BBOT, with approximately 17,878,594 shares worth $0.14B as of Q2 2026.
Yes — 1 widely-followed marquee investor appear among the top 25 institutional holders of BBOT, including CITADEL ADVISORS LLC.
Our composite Smart Money Score for BBOT is 54 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
16 institutions opened new positions in BBOT during Q2 2026, while 18 fully exited. 12 added to existing positions and 35 trimmed.
BBOT institutional ownership rose by 2.09 percentage points quarter-over-quarter, with a net change of -2 holders.
The top 10 institutions account for 75.3% of all reported 13F value in BBOT, and the top 25 account for 96.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
BridgeBio Oncology Therapeutics Inc. (BBOT) Institutional Ownership